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Abstract
Background: although preoperative RT (Radiation Therapy) is becoming the preferred approach
for combined treatment of locally advanced rectal adenocarcinoma, no regimen can be now
considered as a standard. Since the toxicity of preoperative RT isn't yet completely known, and the
advantages of preoperative RT could be counterbalanced by increased postoperative morbidity and
mortality, a monocentre series of preoperative bifractionated accelerated RT was retrospectively
reviewed to clarify toxicity and outcomes after a prolonged follow up.
Methods:  patients were screened following these eligibility criteria: histology-proven
adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical
stage T3–4/anyN, or anyT/N1–2; ECOG Performance Status 0–2. A total dose of 41.6 Gy (26 twice
daily fractions of 1.6 Gy) was delivered. Surgery was carried out 17 ± 2 days after RT completion,
adopting the total mesorectal excision technique.
Results: 24 men and 23 women were enrolled; median age was 55 years (r.: 39–77). Twenty-eight
patients were stage II and 19 stage III. 9 patients suffered from a recurrent tumour. 2 patients
experienced a severe grade 4 gastrointestinal toxicity (a colo-vaginal fistula and an intestinal
obstruction, both successfully treated). Operative mortality was nil; postoperative early
complications occurred in 13 cases; mean length of hospital stay was 15 days. After a mean follow
up of 44 months (r.: 18–84) 8 patients had deceased for recurrent disease, 15 were alive with a
disease progression (2 pelvic recurrences and 13 pure distant deposits) and 24 were alive, without
disease. The 5-year actuarial overall survival was 74.2%, the disease-free survival 62.9% and the
regional control rate 84.7%. Long-term complications included 1 case of radiation enteritis
requiring surgery, 2 cases of anastomotic stricture and 3 cases of bladder incontinence.
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Conclusion: bifractionated accelerated RT administered in the preoperative setting to patients
bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly
infectious) is acceptably low and long-term survivals are achievable. These findings support the
increasing use of preoperative RT for treatment of this malignancy in experienced centres. Ongoing
multicentric trials are expected to address still unsolved issues, including the benefit of CT adjunct
to preoperative RT.
Background
Surgery remains the primary modality of treatment for
rectal cancer and is the only therapy required for early-
stage disease. Locally advanced rectal adenocarcinoma
(i.e. resectable cancer with transmural spread and/or lym-
phatic nodes involvement) continues indeed to represent
a major challenge to surgeons. Although remarkable
progress has been made during the past two decades in
improving surgical techniques, tumours in the lower half
of the rectum pose specific technical problems, and a rad-
ical R0 resection of the tumour and its lymphatic compo-
nent may be difficult to obtain, especially when a huge
lesion is located in a very narrow pelvis of a male patient.
Several studies have recently focused attention on the
importance of standardized surgical technique of total
mesorectal excision [1,2] as well as its integration with
chemo-(CT) and radiation therapy (RT) for optimal treat-
ment of this malignancy [3,4]. Although preoperative RT
is becoming the preferred approach to locally advanced
rectal cancer in many Institutions and large randomised
trials have shown that preoperative RT can substantially
decrease local failure rates and slightly improve overall
survival [5,6], no RT regimen can be now considered as a
standard, and ongoing studies are still addressing some
major unresolved issues, including the optimal timing of
RT (preop- vs postoperative) and the relative merits of
short vs long-course RT. A major concern raised from a
recent meta-analysis, showing a consistent increase in
noncancer-related mortality for patients receiving preop-
erative RT [7]; since the toxicity of preoperative RT seems
to be not yet completely known, and the advantages of
preoperative RT could be counterbalanced by increased
postoperative morbidity and mortality, as seen in some
trials [8], we decided to retrospectively review our series of
preoperative bi-fractionated accelerated RT in locally
advanced rectal cancer, in the attempt to identify risk fac-
tors for early and late toxicity (if any), and to define most
significant oncologic and functional outcomes after a pro-
longed follow up.
Methods
After being informed and giving their consent, 47 consec-
utive patients from the European Institute of Oncology in
Milan were enrolled in this study. The eligibility criteria
included the following: histology-proven adenocarci-
noma of the rectum; distal tumour extent within 12 cm
from the anal verge; clinical stage T3–4/anyN, or anyT/
N1–2 for primary or recurrent disease as well; no evidence
of distant deposits; ECOG Performance Status 0–2; age
>18 years; no prior or concurrent malignancy, and finally
no prior RT. Adjuvant CT was allowed for eligible patients,
suffering from recurrent carcinoma of the rectum.
Pre-treatment evaluation included complete physical
examination, digital rectal examination, common labora-
tory biochemical test, CEA (Carcinoembryonic Antigen)
determination, colonoscopy, CT-scan (Computerized
Tomography) of the thorax, abdomen and pelvis, and
EUS (endoscopic rectal ultrasonography). Total dose
delivered was 41.6 Gy in 26 fractions of 1.6 Gy, two times
daily with at least a 6-h interval. The target volume
included the tumour and each enlarged lymph node (if
any), with a margin of at least 3 cm, perirectal and internal
iliac lymph nodes, the presacral area and surrounding
organs considered to be involved by tumour. A four-field
technique (box) was always used. Dosimetry was opti-
mised by means of a treatment-planning computerized
program, on the basis of either patient's contours or dosi-
metric CT scan. High energy photons of at least 15 MV
were used.
Surgery was scheduled after a rest period of 17 ± 2 days
from RT completion. Total mesorectal excision technique
was always adopted. Adjuvant CT (5 FU + Folinic Acid
bolus) for a 6-month period was planned for patients who
had T4 or N+ at pathology report of surgical specimen.
Results
Table 1 summarizes patients' population pertinent char-
acteristics. 47 patients were treated (24 men and 23
women); the median age was 55 years (r.: 39–77). Pre-
treatment clinical staging included 28 cases stage II and 19
stage III. 9 patients suffered from a recurrent tumour.
Median distance between the lower tumour edge and the
anal verge was 5 cm (range: < 1 – 12).
Three patients did not complete the planned RT schedule
as a consequence of early toxicity; in these cases the dose
administered was 32, 40 and 40.8 Gy respectively.
Table 2 shows the observed toxicity; severe grade 4 gas-
trointestinal reactions included a colo-vaginal fistula,International Seminars in Surgical Oncology 2007, 4:23 http://www.issoonline.com/content/4/1/23
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while 1 patient suffered from grade 3 toxicity (intestinal
sub-obstruction). Both were successfully treated. 9 cases
of grade 2 and 19 cases of grade 1 gastrointestinal reac-
tions were detected. One case of grade 2 and 15 cases of
grade 1 urogenital morbidity were observed. 6 cases of
grade 2 and 6 cases of grade 1 haematological toxicity
occurred. Finally, one grade 2 and 7 grade 1 skin toxicity
were observed.
Surgery was performed at a mean interval of 17 ± 2 days
after RT completion, always adopting the total mesorectal
excision technique. Table 3 lists the main surgical features;
abdomino-perineal resection (APR) was carried out in 14
patients, and low anterior resection with mechanical anas-
tomosis in 33. 16 patients had blood peroperative trans-
fusions; a mean of 2 units of packed red blood cells were
administered (r. = 0–5). All operated patients could bene-
fit of a curative surgery, expressed by an R0 procedure
(proximal, distal and circumferential margins free of dis-
ease; the circumferential free margin resulted less than 1
mm in 9 cases).
None patient obtained a complete pathology response to
the treatment. Downstaging, expressed as pathologic
ypT1–2, ypN0 stage, occurred in 3 patients only. A post-
RT pathology stage ypT1 was detected in 1 case, ypT2 in 7,
ypT3 in 33 and ypT4 in 6. Positive nodes were detected in
33 patients. Mean length of hospital stay was 15 days
(range: 8–35). YpT4-any N and N positive patients under-
went adjuvant chemotherapy for a median of 6 months (5
FU + Folinic Acid bolus).
Postoperative complications occurred in 13 cases (a
detailed list is presented in Table 4): two anastomotic
leaks (both requiring a re-operation), two cases of pro-
longed postoperative ileus, one pelvic abscess (causative
agent: P. aeruginosa) and eight cases of surgical site infec-
tion (SSI) grade I-II, according to CDC classification (peri-
neal and/or laparotomy wound).
After a mean follow up of 44 months (range: 18–84)
(Table 5), six patients experienced severe late complica-
tions: three cases of grade 3 gastrointestinal toxicity (1
radiation enteritis requiring surgery and 2 cases of anasto-
motic stricture requiring serial endoscopic dilatations)
and three cases of grade 3 urogenital toxicity (vescical
incontinence). No case of severe cardiovascular toxicity
occurred. 8 patients (6 of them affected from recurrence of
previous rectal cancer) had deceased for recurrent disease
(pelvic recurrence and concomitant distant metastases),
15 were alive with a disease progression (2 pelvic recur-
rences and 13 pure distant deposits) and 24 were alive,
without disease. The 5 year actuarial overall survival was
74.2%, the disease-free survival 62.9% and the regional
control rate 84.7%.
Table 4: postoperative early complications
Type No. of cases %
Anastomotic leak 2 (out of 33) 6.0
Prolonged postoperative ileus 2 (out of 47) 4.2
Abdominal abscess 1 (out of 47) 2.1
Surgical site infections (grade I-II)* 8 (out of 47) 17.0
All 13 (out of 47) 27.6
*according to CDC classification of Surgical Site Infections
Table 2: observed acute toxicity from preoperative radiation 
therapy
Type Grade 1 Grade 2 Grade 3 Grade 4
Gastrointestinal 19 9 1 (intestinal 
obstruction)
*
1 
(colovaginal 
fistula)**
Urogenital 15 1 - -
Haematologic 6 6 - -
Skin 7 1 - -
* successful conservative treatment; ** successful en-bloc resection at 
the time of programmed surgery
Table 1: patients' population pertinent characteristics
No. of patients treated 47
Male: Female ratio 24 : 23
Mean age (range) 55 yrs. (39–77)
Primary tumours : recurrences ratio 38 : 9
cTNM Stage II : stage III ratio 28 : 19
Mean distance between tumour edge and anal 
verge (range)
5.0 cm (<1 – 12)
No. of patients who completed RT programme 
as protocol
44 (93.6%)
Table 3: main surgical and pathology features in 47 operated 
patients
Parameter No. %
Low anterior resection 33 70.2
Abdomino-perineal resection 14 29.8
En-bloc resection of other organs 5 10.6
R-0 operation Circumferential free margin < 1 
mm
47 9 100 19.1
Circumferential free margin < 1 mm 9 19.1
Patients having blood peroperative transfusions 
(mean: 2 PRBC; r: 0–5)
91 9 . 1
Downstaging (ypT1-2 ypN0) 3 6.3
ypT1 – ypT2 8 17.0
ypT3 – ypT4 39 83.0
Mean length of hospital stay (days; r) 15 
(8–
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Discussion
At present, a variety of innovative RT schedules aiming at
obtaining minimal treatment toxicity are being tested,
including preoperative bi-fractionated accelerated RT.
Theoretic common advantages of long- and short-course
of preoperative RT include the better tumour radio sensi-
tivity, coming from improved oxygenation of presurgical
field, the reduction in tumour seeding by surgical han-
dling and perhaps the reduced toxicity, due to the lesser
amount of radiated small bowel. A recent meta-analysis of
studies dealing with adjuvant RT for rectal cancer, includ-
ing over 8,000 patients, has reported a reduction of local
recurrence risk by almost 50% by preoperative treatment,
independently from fractionation schedules, compared to
37% of risk reduction for postoperative RT [7]. Practical
and economic considerations provided a major effort for
developing short-course treatments, as the tumoricidal
effect of short-course RT (25 Gy in one week) seems to be
equal to that of long-course (42 to 50 Gy over four to six
weeks), using a variety of schedules [9-11]. Unfortunately,
a single randomised study has compared preoperative
short-course with postoperative RT, delivered over 8
weeks [12]; the reduced local recurrence rate with the
former does not mean a inherent superiority of short vs
long-course and adds little to the debate regarding this
issue. However, a major concern could be the price for
short-course preoperative RT, in terms of increased short-
and long-term toxicity, as previously observed with short-
course RT at other sites. This concern has been highlighted
in the above mentioned meta-analysis, which showed a
significant increase in noncancer-related mortality at one
year of follow up, mainly as a consequence of cardiovas-
cular events in older patients [7]. We did not observe sim-
ilar events in our experience, and is likely that could be the
result of outdated techniques, as there was no increase in
postoperative mortality in patients receiving preoperative
RT according to modern techniques in either the Swedish
Rectal Cancer Trial or the Dutch Trial. With respect to
early toxicity, the investigators from the Swedish trial
reported an increased frequency of postoperative fistulas
and femoral neck and pelvic fractures; moreover, for
patients who underwent a conservative surgery, a signifi-
cantly altered residual sphincter function was found [5].
The Dutch group reported an increase in perineal compli-
cations (essentially infectious) in patients receiving pre-
operative RT compared to surgery alone controls [6]. Our
own data confirm these findings: the vast majority of early
observed toxicity is related to infectious complications of
surgical wounds, whereas anastomotic leaks and pelvic
abscess are less relevant.
Our single case of late small bowel toxicity confirms
another previous evidence, coming from randomised tri-
als and retrospective experiences, that preop-RT may have
fewer adverse effects on long-term bowel function than
postoperative therapy [13,14]. One possible explanation
could be the fact that the radiated rectosgmoid is removed
after neoadjuvant therapy; moreover, this could be the
result of a lower radiation dosage to the small bowel, as it
is much easier to exclude the small intestine from the radi-
ation field in a pelvis free of surgical adhesions by proper
positioning of the patients [15]. Moreover, postoperative
treatment is associated with increased frequency of bowel
movements per day, higher rate of incontinence and
increased use of antidiarrhea medications [16]. In addi-
tion, a large German multi-institutional study reported
that only 37% of expected patients were referred for post-
operative adjuvant treatment, reflecting a surgeons' policy
based on patients' individual risk factors evaluation
instead of TNM stage [17]. In our non-randomised study,
no patients who were continent before treatment devel-
oped incontinence, thus comparing favourably with the
incontinence rates associated with postoperative adjuvant
treatment.
A possible benefit of preoperative therapy is the potential
for downstaging, thus increasing resectability rate and the
possibility of sphincter-preserving surgery. Although the
extent of downstaging appears related to the time interval
between completion of preop RT and surgery, the two
major studies of preoperative radiation therapy in rectal
cancer (Swedish [5] and Dutch [6] trials) scheduled sur-
gery after 1 week and 10 days respectively after the end of
radiation treatment; moreover, in the Swedish trial more
patients in the preoperative RT group had Dukes stage A
or B cancers, whereas in our series only patients with
locally advanced or recurrent disease have been treated. In
the larger Dutch study no difference in the rates of positive
Table 5: long term results (mean follow up: 44 mo., r. = 18–84)
Parameter No. %
Deceased 
(progression of 
disease)
81 7 . 0
Primary tumour 2 25
Recurrent disease 6 75
Alive without 
disease
24 51.0
Alive with disease 15 31.9
Overall local 
recurrences
10 21.2
Pure distant 
metastases
13* 27.6
Urogenital toxicity – 
grade 3
3** 6.3
Gastrointestinal 
toxicity – grade 3
3*** 6.3
* liver 7 cases, lung 4 cases, peritoneum and lymphnodes 2 cases
** bladder incontinence
*** 1 case of radiation enteritis requiring surgery, 2 cases of 
anastomotic stricture requiring serial endoscopic dilatationsInternational Seminars in Surgical Oncology 2007, 4:23 http://www.issoonline.com/content/4/1/23
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circumferential margins has been detected (16% in the
preoperative RT vs 19% of surgery alone); our own data
confirm this evidence: a short course of preop-RT and a
short time-interval before surgery are not able to produce
a significant pathologic downstaging, and complete
responses should not be expected. Our finding of 9 out 47
patients with minimal circumferential free margin at sur-
gery (less than 1 mm) confirms that the biological effect
of radiation can extend beyond the anatomic boundaries
of the lesion, with minimal damage to surrounding nor-
mal tissues.
Minsky et al. studied 22 patients with distal rectal cancers
that had been deemed to require APR for cure, and found
that preoperative RT resulted in significant tumour down-
staging, enabling approximately 90% of patients to
undergo sphincter preservation surgery [18]. Similarly,
Rouanet et al. used preoperative irradiation to treat 37
patients with rectal cancer that was thought to require an
APR [19]; sphincter salvage was possible in 78% of
patients. Francois and co-workers [20], in the only study
specifically designed to explore this issue, randomised a
total of 201 patients to either surgery after 2 weeks or after
6–8 weeks from the completion of the RT; both clinical
and pathologic downstaging were significantly higher in
the longer interval group.
Nonetheless, it's our opinion that achieving a microscopic
tumour-free circumferential margin is an important factor
affecting local pelvic recurrence, and the surgeon's ability
to obtain tumour clearance can be challenged by the phys-
ical constraints of a narrow pelvis, particularly in male
patients. A short course of preop-RT offers the advantage
of decreasing the size ("downsizing") of the tumour
before surgery, increasing the resectability rate of lesions
which were previously deemed unresectable with curative
intent or at high risk of R1–R2 procedures. In our series,
patients with recurrent tumours and those with huge
masses deeply invading the mesorectum had local recur-
rence rates that remain very high, in spite of preoperative
RT administration; that's why our efforts are now directed
to obtain a better local control of these huge lesions by
means of combined preoperative CT-RT treatment, using
higher doses and longer time interval, in agreement with
other groups' reported experiences [21].
Conclusion
In conclusion, bi-fractionated accelerated RT adminis-
tered in the preoperative setting to patients suffering from
locally advanced rectal cancer was safe in terms of early
and long-term toxicity, the latter being expressed as
acceptably low postoperative complications' rate (mainly
infectious) and toxic effects on small bowel. These find-
ings support the increasing use of preoperative RT in the
treatment of locally advanced rectal carcinoma; ongoing
trials are expected to address major unsolved issues,
including the role of combined modality treatment (RT
plus CT) in the preoperative setting.
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